Johannes Kullmer
Bremen, HB, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens.
Journal: Haematologica
Published: February 06, 2024
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry.
Journal: Journal of cancer research and clinical oncology
Published: August 14, 2022
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial.
Journal: Leukemia
Published: July 07, 2020
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 02, 2018
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Journal: The Lancet. Oncology
Published: July 20, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026